US EditionNeoadjuvant Trastuzumab Deruxtecan Improves Pathologic Complete Response in Patients With HER2+ Early Breast Cancer
Summary by Pharmacy Times
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
AstraZeneca’s Trastuzumab deruxtecan therapy receives CDSCO nod to manage HER2- low & ultra-low breast cancer in India - Express Pharma
AstraZeneca India Pharma announced a Central Drugs Standard Control Organisation (CDSCO) approval to import for sale and distribution of Trastuzumab deruxtecan concentrate for solution for infusion 100 mg for an additional indication. The medicine is now indicated as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2- low (IHC 1+ and IHC 2+/ISH-) or HER2- ultralow (IHC0 with membrane staining) breast cancer, w…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
